Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Accumulated Expenses (2022 - 2024)

Inmune Bio's Accumulated Expenses history spans 3 years, with the latest figure at $84000.0 for Q2 2024.

  • For Q2 2024, Accumulated Expenses rose 833.33% year-over-year to $84000.0; the TTM value through Jun 2024 reached $84000.0, up 833.33%, while the annual FY2022 figure was $9000.0, N/A changed from the prior year.
  • Accumulated Expenses for Q2 2024 was $84000.0 at Inmune Bio, up from $56000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $84000.0 in Q2 2024 and bottomed at $9000.0 in Q4 2022.
  • The 3-year median for Accumulated Expenses is $32500.0 (2022), against an average of $41000.0.
  • The largest YoY upside for Accumulated Expenses was 833.33% in 2024 against a maximum downside of 522.22% in 2024.
  • A 3-year view of Accumulated Expenses shows it stood at $9000.0 in 2022, then skyrocketed by 777.78% to $79000.0 in 2023, then grew by 6.33% to $84000.0 in 2024.
  • Per Business Quant, the three most recent readings for INMB's Accumulated Expenses are $84000.0 (Q2 2024), $56000.0 (Q1 2024), and $79000.0 (Q3 2023).